Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.

doi:10.1073/pnas.2208176120

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.

Proceedings of the National Academy of Sciences of the United States of America - 24 Jan 2023

Fortin Jerome, Chiang Ming-Feng, Meydan Cem, Foox Jonathan, Ramachandran Parameswaran, Leca Julie, Lemonnier François, Li Wanda Y, Gams Miki S, Sakamoto Takashi, Chu Mandy, Tobin Chantal, Laugesen Eric, Robinson Troy M, You-Ten Annick, Butler Daniel J, Berger Thorsten, Minden Mark D, Levine Ross L, Guidos Cynthia J, Melnick Ari M, Mason Christopher E, Mak Tak W

Abstract excerpt

Mutations in IDH1, IDH2, and TET2 are recurrently observed in myeloid neoplasms. IDH1 and IDH2 encode isocitrate dehydrogenase isoforms, which normally catalyze the conversion of isocitrate to α-ketoglutarate (α-KG). Oncogenic IDH1/2 mutations confer neomorphic activity, leading to the production of D-2-hydroxyglutarate (D-2-HG), a potent inhibitor of α-KG-dependent enzymes which include the TET methylcytosine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dioxygenases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to Isocitrate Dehydrogenase

Share to Ketoglutaric Acids

Source

Open in PubMed Open full text

Identifiers

PMID: 36652477
DOI: 10.1073/pnas.2208176120
PMCID: PMC9942850

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells.PMID 36652477Read ↗

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.Semantic proximity Read ↗

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesSemantic proximity Read ↗

[IDH mutations activate Hoxa9/Meis1 and hypoxia pathways in acute myeloid leukemia model mice].Semantic proximity Read ↗

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.Semantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

Roles of IDH1/2 and TET2 mutations in myeloid disorders.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in leukemiaSemantic proximity Read ↗

<i>Id1</i> Promotes Clonal Hematopoiesis in Mice with <i>Tet2</i> Loss of FunctionSemantic proximity Read ↗

Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.